DBV Technologies | DBVT - Current Liabilities

Stock Price
19.80
Daily Change
0.46 2.38%
Monthly
-2.32%
Yearly
132.12%
Q2 Forecast
19.35

DBV Technologies reported $49.48M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amarin USD 194.46M 12.23M Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
DBV Technologies USD 49.48M 60K Sep/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Galectin Therapeutics USD 14.62M 1.98M Jun/2024
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
United Therapeutics USD 560.6M 14.3M Dec/2025